Home Tools
Log in
Cart

Search Result

Search Results for " human igg2 "

19

Compounds

Cat No. Product Name Synonyms Targets
T9927 Panitumumab EGFR
Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).
T78243 Human IgG2 kappa, Isotype Control
Human IgG2 kappa Isotype Control is a monoclonal antibody serving as an isotype control specific to human IgG2κ antibodies [1].
T76779 Brodalumab LP 0160,KHK-4827,AMG-827 IL Receptor
Brodalumab (AMG 827) is a human monoclonal antibody targeting interleukin 17 receptor (IL-17R) IgG2, often used as an immunosuppressant in the treatment of psoriasis and psoriasis.
T77439 Glembatumumab Others
Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma.Glembatumumab is a naked antibody to Glembatumumab vedotin and ...
T9920 Evolocumab Others
Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 Proprotein Convertase Subtilisin Kexin Type 9).
T77491 Prezalumab AMG 557 Others
Prezalumab (AMG 557) is a human IgG2 monoclonal antibody against ICOSL and BAFF. Prezalumab can be used to study sjogren's syndrome cutaneous lupus erythematosus, psoriasis, systemic lupus erythematosus arthritis and sys...
T76858 Ascrinvacumab PF-03446962 ALK , TGF-beta/Smad
Ascrinvacumab (PF-03446962) is a highly humanized IgG2 monoclonal antibody against ALK-1. Ascrinvacumab has a Kd value of 7 nM for human ALK1. Ascrinvacumab has an inhibitory effect on TGF-β and can be used to study hepa...
T76829 Tarextumab
Tarextumab (OMP-59R5), a fully human IgG2 monoclonal antibody targeting Notch2/3 receptors, demonstrates anti-tumor activity [1].
T82367 Fulranumab
Fulranumab, a human IgG2 monoclonal antibody targeting nerve growth factor (NGF), is utilized in pain research [1].
T76934 Brazikumab
Brazikumab (AMG 139), a human IgG2 monoclonal antibody, selectively targets the p19 subunit of IL-23 with a dissociation constant (K D) of 0.138 nM, indicating high affinity for human IL-23. It is employed in Crohn's dis...
T78304 Bapotulimab BAY-1905254
Bapotulimab (BAY-1905254) is a fully human IgG2 antibody that targets the immunoglobulin-like domain-containing receptor 2 (ILDR2), exhibiting antitumor and immunosuppressive effects [1].
T76921 Befovacimab
Befovacimab (BAY 1093884), a fully human monoclonal IgG2 antibody, binds to the tissue factor pathway inhibitor (TFPI). It is utilized in research for haemophilia A/B [1].
T76697 Panitumumab (anti-EGFR)
Panitumumab, a fully human IgG2 anti-EGFR monoclonal antibody, exerts anti-tumor effects by inhibiting tumor cell proliferation, survival, and angiogenesis. It is utilized in researching various cancers, including colon ...
T77173 Eflepedocokin alfa
Eflepedocokin alfa is a recombinant fusion protein that exhibits cell protective activity by comprising human IL-22 fused with the human IgG2-Fc domain. This compound activates the IL-22/IL-22R -mediated signal transduct...
T78307 Catumaxomab
Catumaxomab, a trifunctional IgG2 antibody with mouse and rat heavy and light chain components, targets human EpCAM and CD3 receptors. Its Fc region exhibits affinity for FcγRI (CD64), FcγRIIA (CD32a), and FcγRIII (CD16)...
T77450 Vantictumab OMP-18R5
Vantictumab (OMP-18R5), a fully human IgG2 monoclonal antibody, antagonizes Wnt pathway signaling through binding to FZD1/2/5/7/8 receptors. It is currently under investigation for the treatment of various cancers, inclu...
T77037 Insulin efsitora alfa
Insulin efsitora alfa (LY-3209590) is a selective insulin receptor (IR) agonist, comprising a fusion protein that integrates human IR agonists with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2), and ha...
T76791 Seribantumab
Seribantumab (MM 121), a fully human IgG2 monoclonal antibody, specifically targets HER3, inhibiting the activation of the epidermal growth factor receptor (ErbB) family and its subsequent signaling. This action effectiv...
T76974 Tafolecimab
Tafolecimab (IBI-306), a human IgG2 monoclonal antibody, specifically targets and binds to PCSK-9, thus inhibiting PCSK-9-mediated endocytosis of the LDL receptor. This action enhances the clearance of LDL-C, resulting i...
TargetMol